Connect with us

Hi, what are you looking for?


Single-cell Spatial Analysis May Help Predict Response to Neoadjuvant Immunotherapy in Triple-negative Breast Cancer

A next-generation technology that allows the study of protein expression at the single-cell level and the location of the cells within the tumor microenvironment (TME) was feasible and provided information on the benefit of adding the immune checkpoint inhibitor atezolizumab (Tecentriq) to chemotherapy as neoadjuvant treatment for patients with early high-risk and locally advanced triple negative breast cancer (TNBC), according to results presented at the San Antonio Breast Cancer Symposium, held December 7-10, 2021.

Original Source:

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like